Perspective Therapeutics在2025年ESMO大会上报告了44%的确认缓解率和87.5%的无进展患者接受[212 Pb]VMT-α-NET治疗

2025-10-20 16:34

Updated interim results with an additional ~19 weeks of follow-up since the prior update
[212Pb]VMT-α-NET continues to be well-tolerated
Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on study
Initial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026
Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET